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This article prepared by the EADV Task Force on Melanoma
aims at providing consensus-based recommendations on how to
address the main challenges in management of patients with
cutaneous melanoma during the COVID-19 pandemic.1,2
1 In-person physical examinations remain irreplaceable for
patients who have noticed new suspicious lesions or are
referred by a clinician with a lesion suspicious for melanoma.
For individuals who need periodical examinations due to
increased melanoma risk, intervals between visits may be
extended by a maximum of 2–3 months. For routine check-
ups, the use of teledermatology is recommended. These
efforts aim at limiting the risk of potential exposure to
COVID-19.
2 Dermoscopy remains the gold standard for diagnosis of mel-
anoma. Even though no transmission of COVID-19 via der-
matoscopes has been reported, dermoscopy should be
performed with careful desinfection between patients, to
avoid the transmission of infectious agents, including bacte-
ria, fungi and viruses. Epidemiological triage, proper hand
hygiene and adequate personal protection equipment by
physicians and patients are warranted.
3 Once a lesion is clinically suspicious of melanoma, an exci-
sional biopsy with the intent to remove the whole clinically
visible lesion should be performed as soon as possible. The
timing of additional surgical procedures might require modi-
fication depending on the availability of operating rooms. A
proposed approach after complete excision of primary mela-
noma during restrictions and limitations due to the pan-
demic is shown in Table 1.
4 In case of a COVID-19 lockdown, follow-up visits and imag-
ing procedures may be postponed in asymptomatic patients
with melanoma stage 0-IIA by up to 3 months. Teleconsulta-
tions with asymptomatic patients can help to foster the physi-
cian-patient relationship, reassure patients and strengthen
compliance. Tumour-free, high-risk patients should continue
to have physical and imaging examinations especially during
the first 3 years after surgery of the primary tumour. All
patients should be educated and encouraged to perform skin
self-examination once per month.
5 Adjuvant melanoma treatment with approved drugs is rec-
ommended during the COVID-19 pandemic and should be
initiated within the first 12 weeks after complete resection.
PD-1 antibodies should be given using the longest approved
treatment intervals: pembrolizumab 400 mg q6w and nivolu-
mab 480 mg q4w.8 Targeted therapy allows for less frequent
hospital visits, shorter time spent in the hospital/facility and
telemedicine symptom checks. Yet, one needs to consider
that the frequently occurring adverse event pyrexia might
trigger false alarms in people and physicians unfamiliar with
the safety profile of the dabrafenib + trametinib drug combi-
nation.
6 Melanoma patients with unresectable or metastatic disease
always require systemic therapy. Patients with active malig-
nant diseases are at increased risk for a severe course of
COVID-19 and thus need to be informed to strictly adhere to
recommended safety and hygiene procedures (Table 2).
Patients requiring targeted therapy, the combination of enco-
rafenib and binimetinib (if available), should be considered
over other BRAF and MEK inhibitors (lower rate of pyrexia).
For the majority of patients requiring immunotherapy, it is
Table 1 Practical approach to melanoma surgery during the
COVID-19 pandemic
Wide excision should be performed as soon as possible but within 3 months
at the latest for both melanoma in situ and invasive melanoma3,4
Sentinel lymph node biopsy may be delayed by up to 3 months5,6
Therapeutic lymph node dissection should be limited to patients with
clinically evident regional lymph node metastases7
High surgical priority should be given to all invasive primary melanomas,
resectable stage III melanomas and oligo-metastatic disease
Table 2 General recommendations for melanoma care at a glance
The COVID-19 pandemic mandates precautions to minimize the risk of
infections, while ensuring most effective cancer care
Teledermatology is a valuable tool in times of lockdown and limitation of
face-to-face visits
The initiation of adjuvant and therapeutic melanoma therapy should not be
delayed during the COVID-19 pandemic
Treatment decisions require the consideration of individual risk factors and
melanoma characteristics
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recommended to start monotherapy with anti-PD-1 inhibi-
tors due to their favourable safety profile.9Some patients
might still require treatment with the combination of anti-
PD-1 and anti-CTLA-4 inhibitors. This includes patients with
symptomatic and asymptomatic brain metastases, but also
patients with elevated LDH levels, bulky disease, PD-L1 nega-
tivity, mucosal and acral melanoma.
7 Melanoma patients are at increased risk of a severe COVID-
19 disease course and should receive priority access to SARS-
CoV-2 vaccines. A panel of oncology and infectious disease
experts agreed that the Pfizer/BioNTech and Moderna vacci-
nes are safe and effective for the general population. To date,
there is no evidence that these vaccines should not be safe for
cancer patients.10
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